ARS Pharmaceuticals, Inc.SPRYNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank0
3Y CAGR-10.5%
5Y CAGR-1.3%
Year-over-Year Change
Research and development spending
3Y CAGR
-10.5%/yr
vs +5.6%/yr prior
5Y CAGR
-1.3%/yr
Recent deceleration
Acceleration
-16.0pp
Decelerating
Percentile
P0
Near historical low
vs 5Y Ago
0.9x
Contraction
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $13.18M | -32.7% |
| 2024 | $19.58M | -3.4% |
| 2023 | $20.27M | +10.3% |
| 2022 | $18.38M | -9.4% |
| 2021 | $20.27M | +44.1% |
| 2020 | $14.07M | -34.6% |
| 2019 | $21.50M | +45.3% |
| 2018 | $14.80M | - |